{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:37:26Z","timestamp":1785893846241,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ecl.2024.09.003","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T21:12:54Z","timestamp":1738789974000},"page":"85-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options"],"prefix":"10.1016","volume":"54","author":[{"given":"Sarah H.","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J.","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ecl.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"e59114","DOI":"10.1371\/journal.pone.0059114","article-title":"Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans","volume":"8","author":"Hinkle","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ecl.2024.09.003_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ajcn\/88.4.906","article-title":"Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight","volume":"88","author":"Rosenbaum","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"10.1016\/j.ecl.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI25977","article-title":"Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight","volume":"115","author":"Rosenbaum","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"17","key":"10.1016\/j.ecl.2024.09.003_bib4","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib5","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1152\/ajpregu.00053.2009","article-title":"Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects","volume":"298","author":"Goldsmith","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"25 Pt B","key":"10.1016\/j.ecl.2024.09.003_bib6","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines and the obesity society","volume":"63","author":"Jensen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ecl.2024.09.003_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2024.09.003_bib8","article-title":"FDA 2007 draft guidance for industry. Developing products for weight management. U.S. Department of health and human services","year":"2007","journal-title":"Food and Drug Administration"},{"key":"10.1016\/j.ecl.2024.09.003_bib9","series-title":"Recognition of obesity as a disease","article-title":"Policy H-440.842","year":"2013"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: a systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ecl.2024.09.003_bib12","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.ecl.2024.09.003_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ecl.2024.09.003_bib14","series-title":"GlaxoSmithKline consumer healthcare","author":"Moon Township","year":"2015"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/clpt.1994.104","article-title":"Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers","volume":"56","author":"Zhi","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"7631","key":"10.1016\/j.ecl.2024.09.003_bib17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2024.09.003_bib18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A\u00a0randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.ecl.2024.09.003_bib19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A\u00a06-month randomized, placebo controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"issue":"4","key":"10.1016\/j.ecl.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pcad.2013.09.005","article-title":"Weight loss strategies for treatment of obesity","volume":"56","author":"Kushner","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.ecl.2024.09.003_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"10.1016\/j.ecl.2024.09.003_bib22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ecl.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"10321","key":"10.1016\/j.ecl.2024.09.003_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"issue":"9741","key":"10.1016\/j.ecl.2024.09.003_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ecl.2024.09.003_bib28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.ecl.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2024.09.003_bib32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2024.09.003_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ecl.2024.09.003_bib35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"10.1016\/j.ecl.2024.09.003_bib36","first-page":"220","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent brainstem areas involved in regulation of appetite and glucose homeostasis","volume":"18","author":"Knudsen","year":"2016","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.ecl.2024.09.003_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10278","key":"10.1016\/j.ecl.2024.09.003_bib38","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ecl.2024.09.003_bib39","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ecl.2024.09.003_bib40","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2024.09.003_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10402","key":"10.1016\/j.ecl.2024.09.003_bib42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2024.09.003_bib43","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","author":"Aronne","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2024.09.003_bib44","series-title":"A\u00a0study of tirzepatide (LY3298176) in participants with obesity or overweight with weight related comorbidities (SURMOUNT-5)","year":"2023"},{"issue":"11","key":"10.1016\/j.ecl.2024.09.003_bib45","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.ecl.2024.09.003_bib46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"10.1016\/j.ecl.2024.09.003_bib47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9741","key":"10.1016\/j.ecl.2024.09.003_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ecl.2024.09.003_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2024.09.003_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2024.09.003_bib51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:30:54Z","timestamp":1750253454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852924000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0889852924000689"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2024.09.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}